REGENXBIO Cash Flow Statement
NASDAQ: RGNXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
8.07-0.02 (-0.25%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
REGENXBIO free cash flow
In fiscal 2025, REGENXBIO generated -$124.0 million of operating cash flow and spent $2.4 million on capital expenditures. That left free cash flow of -$126.4 million, a free-cash-flow margin of -74.1% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
REGENXBIO cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -193.88M | -227.10M | -263.49M | -280.32M | 127.84M | -111.25M | -94.73M | 99.94M | -73.17M | -62.97M |
| Net Income growth (YoY) | — | — | — | -319.27% | — | — | -194.79% | — | — | — |
| Depreciation & Amortization | 15.62M | 16.21M | 17.32M | 12.91M | 9.56M | 8.41M | 7.15M | 3.98M | 2.69M | 544.00K |
| Stock-Based Compensation | 34.56M | 38.46M | 40.27M | 40.79M | 38.81M | 31.95M | 26.85M | 16.64M | 10.61M | 7.03M |
| Change in Working Capital | 16.34M | 6.77M | -2.88M | 30.56M | 11.20M | -7.25M | -8.22M | -12.86M | 3.05M | 1.12M |
| Operating Cash Flow | -123.96M | -173.13M | -218.41M | -207.49M | 218.88M | -54.06M | -107.70M | 104.65M | -57.99M | -48.56M |
| Capital Expenditures | -2.41M | -2.44M | -9.96M | -30.72M | -84.17M | -26.87M | -11.72M | -13.28M | -7.16M | -8.15M |
| Investing Cash Flow | -15.87M | 103.45M | 190.94M | -11.93M | -406.64M | 122.76M | 93.56M | -279.36M | -4.79M | 19.39M |
| Financing Cash Flow | 116.77M | 92.68M | -34.97M | -28.84M | 195.25M | 200.21M | 8.38M | 204.44M | 84.60M | 119.00K |
| Net Change in Cash | -23.06M | 23.00M | -62.43M | -248.26M | 7.48M | 268.91M | -5.77M | 29.73M | 21.82M | -29.05M |
| Free Cash Flow | -126.38M | -175.56M | -228.37M | -238.21M | 134.70M | -80.93M | -119.42M | 91.37M | -65.15M | -56.71M |
This table shows 10 annual periods of REGENXBIO's cash flow statement, from FY 2025 back to FY 2016, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RGNX's reporting calendar. What is a cash flow statement?